Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -4.36% | 352.43 | 0.0% | $5529.05m | |
| BNTX | BioNTech SE | -2.97% | 351.74 | 0.0% | $1554.09m | |
| NVAX | Novavax, Inc. | 7.56% | 208.63 | 78.2% | $1149.83m | |
| AMGN | Amgen, Inc. | -2.26% | 198.88 | 1.4% | $591.30m | |
| LGVN | Longeveron Inc. | 0.04% | 26.26 | 0.0% | $511.78m | |
| GILD | Gilead Sciences, Inc. | -2.44% | 68.93 | 1.0% | $497.91m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.73% | 636.53 | 2.7% | $490.45m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.67% | 186.94 | 1.9% | $375.32m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 0.88% | 4.61 | 0.7% | $322.26m | |
| ILMN | Illumina, Inc. | -1.48% | 365.33 | 3.3% | $311.28m | |
| OCGN | Ocugen, Inc. | -1.40% | 6.34 | 0.0% | $293.70m | |
| BIIB | Biogen, Inc. | -0.16% | 235.74 | 1.8% | $289.61m | |
| EXAS | EXACT Sciences Corp. | -1.39% | 85.37 | 18.0% | $167.68m | |
| INCY | Incyte Corp. | -3.77% | 67.72 | 2.4% | $165.57m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.27% | 86.29 | 4.2% | $144.64m |
Company Profile
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.